@article{bba84ace79f5446f9624f865253df1f6,
title = "A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer",
abstract = "In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove drug efficacy.",
keywords = "FDA, immunotherapy, small cell lung cancer, surrogate endpoints",
author = "Jennifer Gill and Cetnar, {Jeremy Paul} and Vinay Prasad",
note = "Funding Information: V.P. receives royalties from his book Ending Medical Reversal. His work is funded by Arnold Ventures, he has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, and professional societies, is a writer for Medscape, and the host of the Plenary Session podcast, which receives crowdfunding support through the Patreon platform. J.G. and J.C. declare no competing interests. Publisher Copyright: {\textcopyright} 2020 Elsevier Inc. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.",
year = "2020",
month = sep,
doi = "10.1016/j.trecan.2020.05.014",
language = "English (US)",
volume = "6",
pages = "736--738",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "9",
}